 Connection
Kevin Ess to Everolimus
This is a "connection" page, showing publications Kevin Ess has written about Everolimus.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.450 |
|
|
|
-
Ess KC, Franz DN. Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred. Neurology. 2019 07 09; 93(2):51-52.
Score: 0.155
-
Krueger DA, Capal JK, Curatolo P, Devinsky O, Ess K, Tzadok M, Koenig MK, Narayanan V, Ramos F, Jozwiak S, de Vries P, Jansen AC, Wong M, Mowat D, Lawson J, Bruns S, Franz DN. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience. Eur J Paediatr Neurol. 2018 Nov; 22(6):1066-1073.
Score: 0.145
-
Ess KC, Roach ES. New therapies for tuber-less sclerosis: white matter matters? Neurology. 2012 Feb 21; 78(8):520-1.
Score: 0.093
-
Edwards DN, Wang S, Kane K, Song W, Kim LC, Ngwa VM, Hwang Y, Ess K, Boothby MR, Chen J. Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowth. JCI Insight. 2025 May 08; 10(9).
Score: 0.058
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|